Clinical trials: Semaglutide
Alzheimer Disease (AD)
Improved Treatment and Monitoring of Alzheimer's Disease
In the world's high-income countries, Alzheimer's disease and other dementia diseases are currently the second most common cause of death.
- Trial name
- NCT07135245
- Testing
- Semaglutide (Rybelsus®) combined with other interventions, Semaglutide (Rybelsus®)
- Volunteers
- 180 people
- Sponsor
- Rune Skovgaard Rasmussen
Childhood Obesity, Treatment Adherence
The Evira Study: Additional Support During Obesity Treatment
The goal of this clinical trial is to evaluate the effect of adding a digi-physical treatment tool as a complement to the local treatment with obesity medication in adolescents with obesity.
- Trial name
- NCT06836284
- Testing
- Digi-physical treatment tool, Evira, Obesity medication with liraglutide or semaglutide
- Where
- 3 sites in Sweden
- Volunteers
- 40 people
- Sponsor
- Karolinska Institutet
Obesity
Bariatric Surgery Combined With GLP-1RA: A Multicenter Study.
Obese patients exhibit considerable heterogeneity and complex comorbidities, making long-term effective management challenging with single therapies.
- Trial name
- BS-GLP (NCT07732738)
- Testing
- BS-GLP1RA group, BS group
- Where
- 7 sites in China
- Volunteers
- 400 people
- Sponsor
- China-Japan Friendship Hospital
Pregnancy, Obesity
A Study to Evaluate the Safety of Exposure to Wegovy During Pregnancy
This is an observational cohort study using administrative insurance claims data. The aim of this non-interventional study (NIS) is to compare maternal, fetal and infant outcomes of women exposed to Wegovy during pregnancy to a…
- Conditions
- Pregnancy, Obesity, Overweight
- Trial name
- NCT05503927
- Testing
- No Intervention
- Where
- 2 sites in United States
- Volunteers
- 2,701 people
- Sponsor
- Novo Nordisk A/S
Glucagon Like Peptide-1 (GLP-1, Delayed Gastric Emptying
GLP_1 RA Ultrasound Study
The purpose of the study is to determine whether patients taking GLP-1 RAs have increased residual (left behind), gastric (stomach), contents due to delayed gastric emptying when following standard preoperative fasting guidelines.
- Conditions
- Glucagon Like Peptide-1 (GLP-1, Delayed Gastric Emptying, Risk of Aspiration, Diabetes
- Trial name
- NCT06581120
- Testing
- Glucagon-Like Peptide-1 receptor agonists, Point of Care Gastric Ultrasound
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Polycystic Ovarian Syndrome in Adolescent Females, Obesity (Disorder)
Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS)
The prevalence of childhood obesity in the United States has more than tripled in the past four decades affecting one in every five adolescent girls and is disproportionally higher among racial and/or ethnic minorities.
- Trial name
- NCT07169136
- Testing
- GLP-1 Receptor Agonists
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Nemours Children's Clinic
Gastric Retention
Impact of Discontinuing GLP-1 Receptor Agonists for Two Weeks Prior to Upper Endoscopy on the Risk of Gastric Retention
A retrospective observational study to explore the impact of discontinuing GLP-1 receptor agonists for two weeks prior to upper endoscopy on the risk of gastric retention
- Trial name
- NCT07276763
- Testing
- No Intervention: Observational Cohort
- Where
- China
- Volunteers
- 16,509 people
- Sponsor
- Fudan University
Type 1 Diabetes, Diabetes Mellitus
Alleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous Semaglutide
A closed-loop insulin system, often labelled the "artificial pancreas" (AP), consists of an insulin pump, a continuous glucose monitor, and an interface coordinating between them to regulate insulin dosage based on glucose…
- Trial name
- SEMA SMA (NCT06387199)
- Testing
- Semaglutide with 4 meal strategies
- Where
- Canada
- Volunteers
- 26 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Lactation, Weight Loss
Effects of GLP-1 RAs on Human Lactation Outcomes
There is increasing interest in using GLP-1 Receptor Agonist (GLP-1 RA) medications after pregnancy. This study is designed to determine if these medications affect breastmilk production or the nutritional makeup of breastmilk.
- Trial name
- NCT07720414
- Testing
- Injected GLP-1 Receptor Agonists and Dual Agonists
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Obesity
STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss
The study is testing how well semaglutide can help adolescents with excess body weight to lose weight and to maintain weight loss. All participants in the study will receive semaglutide as a weekly injection.
- Trial name
- NCT06571383
- Testing
- Semaglutide
- Where
- 93 sites in United States, Belgium and 11 more
- Volunteers
- 500 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Post-Marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ozempic®
The purpose of this study is to assess the safety of long-term treatment with Ozempic® in patients with type 2 diabetes mellitus. People will get Ozempic® as prescribed by their doctor. People will be in this study about 3 years.
- Trial name
- NCT04469855
- Testing
- semaglutide
- Where
- 414 sites in Japan
- Volunteers
- 3,217 people
- Sponsor
- Novo Nordisk A/S
Obesity, Dental Care for Children
MODERN-Dental: Pediatric Obesity, Cardiometabolic Risks, And Periodontal Disease
The goal of this clinical trial is to assess whether adjunctive dental cleaning can enhance the effects of semaglutide in children with obesity.
- Trial name
- NCT07478653
- Testing
- Dental Cleaning and Oral Hygiene Instruction (OHI), Oral Hygiene Instruction (OHI)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Oelisoa Andriankaja
Non-alcoholic Steatohepatitis
Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)
This study is being done to see if a combination of 2 medicines (called NNC0194-0499 and semaglutide) can reduce liver damage in patients with non alcoholic steatohepatitis (NASH).
- Trial name
- NCT05016882
- Testing
- NNC0194 0499 50 mg/mL, Semaglutide 3 mg/mL, NNC0174 0833 10 mg/mL
- Where
- 255 sites in United States, Australia and 22 more
- Volunteers
- 698 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
The purpose of this clinical study is to look into how well a study medicine called CagriSema helps children and adolescents living with diabetes lower their blood sugar and body weight.
- Trial name
- REIMAGINEYOUNG (NCT07282613)
- Testing
- CagriSema (Cagrilintide B and Semaglutide I)
- Where
- 58 sites in United States, Argentina and 8 more
- Volunteers
- 80 people
- Sponsor
- Novo Nordisk A/S
Craniopharyngioma, Child
SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years
Craniopharyngioma (CP) is a rare embryonic brain tumor of the sellar and parasellar region. Despite its benign histologic characteristics, it is locally aggressive and may cause severe morbidity from invasion into adjacent…
- Trial name
- SEMAFORCRANIO (NCT07845994)
- Testing
- Semaglutide (Wegovy) weekly injection
- Where
- 17 sites in France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Angers
Obesity, Type 2 Diabetes (T2D)
A Retrospective Real-World Cohort Study
The primary objectives are to determine the prevalence and overlap of major cardiometabolic diseases, identify multimorbidity clusters, and characterize demographic, clinical, laboratory, and treatment patterns across the cohort…
- Conditions
- Obesity, Type 2 Diabetes (T2D), Prediabetes, Cardiovascular Disease (CVD)
- Trial name
- SCALA-TK-CM (NCT07781371)
- Testing
- No treatment given
- Where
- Denmark
- Volunteers
- 100,000 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease
The purpose of this study is to understand the role of GLP-1 in the pathogenesis of T2D in youth and explore their potential salutary effects and ability to delay the progressive loss of ß-cell function and reduce hepatic…
- Conditions
- Type 2 Diabetes Mellitus, Impaired Glucose Tolerance, Non-Alcoholic Fatty Liver Disease, Obesity, Childhood
- Trial name
- NCT05067621
- Testing
- Semaglutide Pen Injector
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Yale University
Monogenic Obesity
Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice
This observational study aims to assess the effect of once-weekly s.c. semaglutide 2.4 mg as an adjunct to a calorie-reduced diet and increased physical activity on weight loss, change in hunger, body composition, depression, and…
- Trial name
- NCT07302802
- Testing
- Semaglutide (administered by PDS290 pen-injector)
- Where
- 7 sites in France, Germany and 3 more
- Volunteers
- 70 people
- Sponsor
- Prof. Dr. Martin Wabitsch
Diabetes
Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 Years
The efficacy of long-term treatment with different GLP-1RA (Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc.) was evaluated through 1-4 years of follow-up, and the effects of long-term treatment on blood glucose…
- Trial name
- NCT05990374
- Testing
- Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Obesity in Children, Bone Strength
Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist Therapy
The goal of this clinical trial is to compare bone health markers over 24 months in participants 12 - 21 years of age with obesity who are starting the glucagon-like peptide-1 receptor agonists (GLP-1RAs) as compared to those…
- Conditions
- Obesity in Children, Bone Strength, GLP - 1, Lifestyle Modification
- Trial name
- NCT06903923
- Testing
- GLP-1 receptor agonist, Lifestyle intervention
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Virginia